When it comes to the state of the microarray market in 2012, two of the segment's three remaining large players apparently see the major indicators the same way.

For Illumina CEO Jay Flatley and Affymetrix CEO Frank Witney, the future commercial potential of the maturing technology lies in applied markets, including cytogenetics, agricultural biotechnology, and direct-to-consumer services, rather than in the large array-driven genome-wide association or gene expression studies of years ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.